AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUN 20 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - A dendritic cell (DC) vaccine pulsed with peptide of tumor-associated antigen MUC1 can control tumor growth in both human MUC1-transgenic (Tg) mice and in wild-type (WT) mice, say researchers at the University of Pittsburgh, Pennsylvania.
In a report published in the Journal of Immunology, M.M. Soares and colleagues described the results of three MUC1 vaccines for tumor suppression in mice.
"Boosting MUC1-specific immunity with vaccines, especially effector mechanisms responsible for tumor rejection, is an important goal, said Soares and colleagues.
The researches administered either MUC1 peptide and murine GM-CSF adjuvant, MUC1 peptide and SB-AS2 adjuvant, or MUC1 peptide-pulsed dendritic cells (DC) to the two types of mice.
They found that although the two adjuvant-based vaccines induced MUC1-specific immunoglobulin (Ig) responses, that did not translate to T-cell responses that could control tumor growth. Specifically, MUC1 plus GM-CSF induced IgG1 and IgG2b in WT mice but only IgM in MUC1-Tg mice. MUC1 plus SB-AS2, meanwhile, induced high levels of IgG1, IgG2b, and IgG3 antibodies in both WT and MUC1-Tg mice.
The MUC1 DC vaccine, on the other hand, induced only T-cell immunity although when injected with soluble MUC1 peptide, it triggered ...